Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outlook Therapeutics, Inc. (OTLK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retina diseases such as wet AMD, and its filings give detailed insight into how this program is progressing through clinical, regulatory, and commercial stages.
Form 8-K current reports are particularly important for OTLK, as they document material events such as the resubmission of the Biologics License Application (BLA) for ONS-5010, FDA classification of the resubmission as a Class 1 review with an associated PDUFA goal date, and the completion of a Type A meeting to discuss a complete response letter (CRL). Other 8-K filings cover executive appointments and departures, stock option inducement grants, and the release of quarterly and annual financial results.
Investors can also use SEC filings to track Outlook Therapeutics’ listing details on The Nasdaq Stock Market LLC under the symbol OTLK, as well as to review risk factor discussions, financial condition, and updates on the NORSE clinical trial program and commercial launch activities referenced in periodic reports. These documents complement the company’s press releases by providing formal, structured descriptions of key events and agreements.
On Stock Titan, Outlook Therapeutics filings are updated as they are made available on EDGAR. AI-powered tools summarize lengthy disclosures, highlight the main points from forms such as 8-Ks and periodic reports, and make it easier to understand technical language around FDA interactions, clinical data references, and compensation arrangements. This allows readers to quickly grasp what each filing means for ONS-5010/LYTENAVA™, the company’s regulatory pathway, and its overall corporate developments.
Outlook Therapeutics completed a best-efforts public offering of common stock and warrants. The company sold 20,000,000 shares of common stock with accompanying warrants to purchase up to 20,000,000 shares at a combined public price of $0.25 per share-and-warrant.
Gross proceeds were approximately $5.0 million, with net proceeds of about $4.0 million after placement agent fees and expenses. The investor warrants are exercisable immediately at $0.25 per share and expire five years from issuance, subject to 4.99% or 9.99% beneficial ownership caps.
H.C. Wainwright & Co. received cash fees and 1,400,000 placement agent warrants exercisable at $0.3125 per share, also for five years. The company agreed to certain lock-up and no variable-rate issuance covenants, and used an existing Form S-3 shelf registration and prospectus supplement for this transaction.
Outlook Therapeutics, Inc. is offering 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares, at a combined public offering price of $0.25 per share and accompanying warrant. The offering includes placement agent warrants to purchase 1,400,000 shares (7.0% of shares sold) exercisable at $0.3125. Delivery of securities is expected on or about March 25, 2026.
The prospectus supplement states net proceeds to the company from a full subscription would be approximately $4.0 million after placement agent fees and estimated expenses, but this is a best-efforts offering with no minimum amount required to close. The company reported 84,614,219 shares outstanding as of March 20, 2026 and discloses substantial liquidity needs, existing convertible notes, recent FDA complete response letters for ONS-5010/LYTENAVA, and regulatory and financing risks described under "Risk Factors."
Outlook Therapeutics, Inc. is offering shares of common stock, pre-funded warrants and common warrants pursuant to a preliminary prospectus supplement to a registration statement (Reg. No. 333-278340). The offering pairs each share (or pre-funded warrant) with a common warrant exercisable for one share and expiring five years after issuance.
The company reports 84,614,219 shares of common stock outstanding as of March 20, 2026 and a last reported sale price of $0.35 per share on that date. As of December 31, 2025, cash and cash equivalents were $8.7 million. Debt highlights: a $33.1 million promissory note issued March 13, 2025 (the March 2025 Note) convertible into common stock, of which Avondale converted $6.9 million into shares at a weighted average price of $0.46 as of March 20, 2026; an agreement to issue an $18.36 million note on March 16, 2026 to partially repay the March 2025 Note, leaving approximately $9.7 million remaining under the March 2025 Note as of March 20, 2026.
The company discloses three FDA Complete Response Letters regarding its BLA for ONS-5010/LYTENAVA and ongoing regulatory engagement; the FDA has indicated confirmatory evidence of efficacy is required. Outlook has EU and UK marketing authorizations and launched in initial markets. The prospectus warns of substantial doubt about Outlook’s ability to continue as a going concern and Nasdaq noncompliance with the $1.00 bid-price rule, with a compliance date of August 17, 2026.
Outlook Therapeutics entered a Note Purchase Agreement with Atlas Sciences, issuing an unsecured promissory note with an original principal balance of $18,360,000. The note was sold at a discount for $17,000,000, which must be used solely to repay $17,000,000 of an existing convertible note held by Avondale Capital.
The new note bears interest at the prime rate plus 3%, with a floor of 9.5%, matures 15 months after closing, includes a 7.5% exit fee on cash payments, and allows Atlas to redeem up to $3,000,000 per quarter starting six months after closing. After repayment, about $10.8 million remains outstanding on the Avondale note, whose maturity was extended to December 31, 2026.
In updated risk factors, the company reports cash and cash equivalents of $8.7 million as of December 31, 2025 plus $2.4 million from at-the-market sales, and states there is substantial doubt about its ability to continue as a going concern without substantial additional capital. It also highlights repeated FDA Complete Response Letters for ONS-5010/LYTENAVA and its heavy dependence on this single product.
Outlook Therapeutics, Inc. announced that its Board of Directors accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. She had served as a Class director and was a member of the Nominating and Corporate Governance Committee.
The Board resolved to reduce its size to nine directors upon her resignation. According to the company, Dr. Haller’s decision was not the result of any dispute or disagreement regarding the company’s operations, policies, or practices, and the Board expressed appreciation for her service.
Outlook Therapeutics, Inc. reported results of its Annual Meeting of Stockholders held on March 10, 2026. Of 73,509,455 common shares outstanding as of the record date, 37,271,431 shares, or approximately 50.70%, were present or represented by proxy, establishing a quorum.
Stockholders elected Class I directors Yezan Haddadin, Faisal G. Sukhtian and Kurt J. Hilzinger to the Board, each to serve until the 2029 Annual Meeting of Stockholders or until a successor is duly elected and qualified. This maintains continuity on the company’s Board of Directors.
Stockholders also ratified the Audit Committee’s selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with strong support. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Outlook Therapeutics reported that it has held a Type A meeting with the FDA to discuss the December 30, 2025 Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an investigational treatment for wet age-related macular degeneration (wet AMD) in the United States.
The discussion focused on the FDA’s remaining concern about “substantial evidence of effectiveness” and on possible regulatory paths forward. The company plans to continue dialog with the FDA and is reviewing regulatory options to advance the program toward potential U.S. approval.
Outlook highlighted that ONS-5010 achieved clinically meaningful, statistically significant visual acuity gains in the NORSE TWO Phase 3 trial and that NORSE EIGHT and other data provide confirmatory efficacy and safety evidence, with no safety concerns identified by the FDA. The product already has Marketing Authorizations in the EU and UK and has been launched in Germany, Austria, and the UK for wet AMD, while remaining investigational in the U.S.
Outlook Therapeutics, Inc. received a notice from Nasdaq that its common stock has closed below $1.00 per share for the last 30 consecutive business days, failing to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s stock remains listed on the Nasdaq Capital Market for now.
Outlook Therapeutics has 180 calendar days, until August 17, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days. If it still does not comply, it may qualify for an additional 180-day period if it meets other initial listing standards and notifies Nasdaq that it intends to cure the deficiency, potentially through a reverse stock split.
If the company cannot regain compliance and is not granted or does not succeed in an extension, its common stock could be delisted from the Nasdaq Capital Market. Outlook Therapeutics states that it intends to actively monitor its share price and evaluate options to resolve the deficiency.
Outlook Therapeutics reported a net loss of $23.1 million for the quarter ended December 31, 2025, compared with net income of $17.4 million a year earlier, driven largely by fair value losses on its convertible note and warrant liability.
Net revenue was negative $1.2 million after a $1.1 million returns reserve increase on UK product and distributor fees, while research and development and selling, general and administrative expenses fell to $3.6 million and $8.6 million, respectively. Cash and cash equivalents were $8.7 million against total liabilities of $56.8 million, leaving a stockholders’ deficit of $38.5 million and prompting substantial doubt about continuing as a going concern.
The company is commercializing LYTENAVA in Germany and the UK but has received three FDA Complete Response Letters for ONS-5010/LYTENAVA in wet AMD and has requested another Type A meeting to discuss potential regulatory pathways. It also triggered a “Major Trigger Event” under its March 2025 unsecured convertible promissory note, increasing the outstanding balance and resetting the conversion pricing formula.
Outlook Therapeutics reported a GAAP net loss attributable to common stockholders of $23.1 million, or $0.38 per share, for the first fiscal quarter ended December 31, 2025, compared with GAAP net income of $17.4 million, or $0.72 per share, a year earlier. On a non-GAAP basis, which excludes fair value changes in promissory notes and warrants, the company’s adjusted net loss narrowed to $13.5 million, or $0.22 per share, from an adjusted net loss of $21.6 million, or $0.89 per share, in the prior-year quarter.
Revenue was reduced by a higher returns reserve tied to short-dated LYTENAVA shipments in the UK, but European unit sales of LYTENAVA more than doubled versus the previous three months. As of December 31, 2025, cash and cash equivalents were $8.7 million against current liabilities of $49.1 million, with total stockholders’ deficit of $38.5 million. The company is expanding LYTENAVA launches across Europe and has requested a Type A meeting with the FDA following a December 30, 2025 Complete Response Letter for its U.S. ONS‑5010 biologics application.